Press releases

ORION clinical trial designed to evaluate EPIC™ Self-Expanding Nitinol Stent System for the treatment of iliac artery disease

Boston Scientific Corporation (NYSE: BSX) today announced it has acquired Intelect Medical, Inc., a development-stage company located in...

Article reported on a study that found about 20 percent of patients who received an implantable cardioverter defibrillator (ICD) did not meet evidence-based guidelines

Acquisition brings Boston Scientific the first fully repositionable device for percutaneous aortic valve replacement to treat severe aortic stenosis

Company prepays $600 million of debt

Company will participate in the conference on January 11, 2011. A live webcast and replay will be available.

Distinguished leader brings broad range of expertise in science, technology, business, education and government

Patients experienced a 50 percent relative reduction in risk of death compared to in-clinic follow-up

Company will participate in the conference on December 1, 2010. A live webcast and replay will be available.

Innovative percutaneous aortic valve replacement system provides entry into emerging market of structural heart disease

INCEPTA™, ENERGEN™ and PUNCTUA™ designed to advance patient care with options to expand appropriate therapy, optimize ventricular pacing and manage heart failure

Awards recognize breakthrough products and technologies that represent a significant leap forward in their respective categories

Company supports efforts of International Diabetes Federation to promote worldwide diabetes education and prevention

Company's November 19, 2010 meeting will be simultaneously webcast; learn how to tune in live or access the replay.

Company implants its first Deep Brain Stimulation device designed to treat Parkinson's

Boston Scientific Corporation (NYSE: BSX) today announced that its newly acquired subsidiary, Asthmatx, Inc., presented two-year...

Proceeds to allow Company to invest in future growth opportunities while also reducing overall debt leverage

Acquisition brings the Alair® Bronchial Thermoplasty System, the first device-based asthma treatment approved by the FDA

Company's fully covered metal stent now approved for use in treating benign biliary strictures

Latest innovation in plastic biliary stent technology includes features for enhanced deliverability, efficiency and procedural control

CEO Ray Elliott notes financial results reflect “strong operating performance despite the challenges facing our industry.”

Major advance in guidewire technology for challenging peripheral interventions

Company will webcast its conference call on Tuesday, October 19. Learn how to tune in or watch the replay.

MADIT II eight-year outcomes analysis shows that one life is saved for every eight patients who receive an ICD

Largest randomized trial to compare the use of drug-eluting stents to bare-metal stents for AMI patients

Company presents one-year clinical data at TCT on its platinum chromium paclitaxel-eluting coronary stent from PERSEUS trial

Results of TAXUS ATLAS clinical program presented at TCT

Nine-month results from PLATINUM clinical program presented at TCT

Indications are important additions, especially as diabetes prevalence continues to increase worldwide

Offers first FDA-approved non-drug procedure for the treatment of severe asthma

FDA approval is based on results from the Company's landmark MADIT-CRT trial

Company to present clinical data on its platinum chromium PROMUS® Element™ and TAXUS® Element™ Coronary Stent Systems

Company to participate in the September 14th conference in New York City; live webcast and replay will be available

Presentations to feature Boston Scientific's pelvic floor reconstruction systems and mid-urethral sling systems

Resolution "marks a major milestone in our journey of continuous quality improvement," said Ray Elliott, President and Chief Executive Officer

EVOLVE trial to evaluate Company's fourth-generation SYNERGY™ drug-eluting coronary stent

Company now offers pain specialists the most comprehensive portfolio of SCS percutaneous leads

Company to participate in the August 5th conference in New York; live webcast and replay will be available

Company expands market-leading family of neurovascular stents

"I am proud of the way the organization executed in a number of key areas during the quarter," said Ray Elliott, President and CEO

Trial data to help develop a clinical alert that identifies the early onset of worsening heart failure

Company to webcast its conference call with Q2 2010 financial results and business highlights on July 21

Two new splitters allow multi-site placement of up to four spinal cord stimulation leads

Refinancing to help strengthen Company’s capital structure and provide enhanced capacity to fund acquisitions and other investments in technologies

Longer balloons provide physicians more options for treating peripheral artery disease

Women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men

Company to participate in the healthcare conference on June 24 in Boston; live webcast and replay will be available

Presentations to include results of the MADIT-CRT trial and the ALTITUDE clinical science program

CE Mark approval includes specific indication for treatment of diabetic patients

Company to participate in the June 16th conference in Los Angeles; live webcast and replay will be available